#divis lab share price

[stockgro]

A Closer Look at The Share Prices Of Sun Pharma Advanced Research Company And Divis Laboratories

The health industry is of the utmost importance to any nation, not just from the wellness index viewpoint, but also from the economic condition viewpoint. It enumerates the quality of life, working conditions of individuals, affordability and availability of healthcare, and so on. With such a profound impact on society at large, it is obvious that the health industry and pharmaceutical companies also have a crucial share in the stock market. 

Those wanting to shortlist their selection for investing in the shares of healthcare background may find two prominent names under the spotlight, i.e. Sun Pharma Advanced Research Company (SPARC) and Divis Laboratories. 

Sun Pharma Advanced Research Company (SPARC)

It is the research and development arm of the eminent Sun Pharmaceutical Industries Limited. Having countless breakthroughs in health, therapy, wellness, and medicine under its hood, SPARC has been in the limelight throughout the time. However, with inevitable challenges, its share value has also seen some adverse positions, making its journey marked by highs and lows.

As a probable investor, one must check with the following factors influencing SPARC's share price.

Pipeline Projects- Advancements in the healthcare industry are responsible for the sustenance of pharma companies. Thus, SPARC's share price is also influenced by its projected developments, research projects, and clinical trials. Positive outcomes may henceforth drive bullish sentiment among investors.

Regulatory Environment- Since the wellness of billions of people is in the hands of pharmaceutical companies, their products and services must be strictly regulated. This is why even SPARC has to undergo stringent regulatory measures for drug approvals, etc. that ultimately affect the company's share price.

Competitive Landscape- Like other industries, competition persists even in the pharmaceutical industry. Research, developments, pricing, product strategy, and other operational activities of competitors may influence the share price of SPARC. Thus, investors closely monitor its competitive positioning. 

In closing, Sun Pharma Adv has demonstrated resilience and growth through innovation, partnerships, and licensing agreements, making the sun pharma adv share price INR 217.50 INR, a +2.95 (1.37%) currently.

Divis Laboratories

Being in operation since the 1990s, Divi's Laboratories is reportedly the fourth largest publicly listed pharmaceutical company by market capitalization, in India. Its active work in manufacturing active pharmaceutical ingredients (APIs) and intermediates has hoarded the company ample appreciation in the healthcare industry. 

Quality and innovation have been its hallmarks for which investors show keen interest in its financial performance and divis lab share price; some governing factors are as follows.

API Demand- Since Divis Labs supplies APIs to pharmaceutical companies globally; its share price gets highly impacted by the demand for its products. In turn, such demand is closely tied to factors including healthcare expenditure, availability of generic drugs, and outsourcing by MNC pharmaceutical firms, influencing Divi Lab’s share price.

Expansion Plans- It is imperative even for the pharma companies, including Divis Labs to aim for expansion of distribution network, manufacturing capacity, and product diversification as it signals growth trajectory to the interested investors, leveraging the value of the share. Contrarily, setbacks in expansion projects may dampen the spirits of the existing and prospective investors.

Supply Chain- Divis Labs is known for its distribution network extended to international areas as well. However, their pharmaceutical supply chain can get disrupted owing to usual factors such as geopolitical developments, trade policies, competition emergence, disruptions in the supply of raw materials, etc., affecting their share price.

As per reports, the divis lab share price has lately come down to INR 3,883.15, a -28.35 (0.72%). However, the growing demand for APIs cannot be overlooked, paving the way for a higher value of its share in the market.

For more information on Divis Lab and sun pharma adv share price, you may read the latest updates published on StockGro. 

[akshat-kapoor]

Understanding Divi's Laboratories Share Price: A Deep Dive

Investors and market enthusiasts often turn their attention to specific stocks that exhibit remarkable performance or promise within the pharmaceutical sector. One such company that frequently garners attention is Divi's Laboratories Limited, commonly known as Divi's Labs. This article delves into the dynamics surrounding Divi's Labs share price, exploring factors that influence it and what investors should consider.

Overview of Divi's Laboratories

Divi's Laboratories, founded in 1990 and headquartered in Hyderabad, India, is a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. The company has established a strong presence in the global pharmaceutical market, focusing on producing high-quality APIs across various therapeutic segments. With state-of-the-art manufacturing facilities and a commitment to innovation and quality, Divi's Labs has carved a niche for itself in the industry.

Factors Influencing Divi's Labs Share Price

1. Financial Performance:

Revenue Growth: Investors closely monitor Divi's Labs' revenue growth, which reflects its ability to capitalize on market opportunities and expand its product offerings.

Profit Margins: The company's profitability, as indicated by its profit margins, is crucial for determining shareholder returns and market sentiment.

Earnings Per Share (EPS): EPS growth is a key metric that influences stock valuation, as it indicates the company's ability to generate profits for its shareholders.

2. Product Pipeline and Innovation:

The pharmaceutical industry relies heavily on research and development (R&D) for sustained growth. Divi's Labs' investments in R&D to develop new APIs and improve existing products can significantly impact its stock price.

Regulatory approvals for new products and manufacturing facilities also play a crucial role in enhancing market confidence and driving share price appreciation.

3. Market Demand and Competitive Landscape:

Demand for pharmaceutical products, especially APIs, is influenced by global healthcare trends, regulatory changes, and economic factors.

Competitor activities and market positioning relative to peers can affect investor perception and consequently, share price movements.

4. Macro-Economic Factors:

Economic conditions, exchange rates (particularly for a company with significant international operations like Divi's Labs), and geopolitical developments can all influence investor sentiment and stock performance.

Interest rates and inflation rates can impact the cost of operations and financing, thereby affecting profitability and stock valuation.

Recent Performance and Outlook

In recent years, Divi's Laboratories has shown robust financial performance, driven by strong demand for its APIs globally. The company has expanded its production capacities and diversified its product portfolio, enhancing its competitiveness in the market. Analysts often provide insights into future growth prospects based on these factors, influencing investor sentiment and share price movements.

Conclusion

Investing in pharmaceutical stocks such as Divi's Laboratories requires careful consideration of both company-specific factors and broader market trends. While past performance and financial indicators provide valuable insights, staying informed about regulatory changes, market demand dynamics, and global economic conditions is crucial for making informed investment decisions.

As Divi's Laboratories continues to navigate the complexities of the pharmaceutical industry, its share price will remain subject to various influences. For investors looking to capitalize on opportunities within the healthcare sector, understanding these dynamics is essential for assessing the potential risks and rewards associated with investing in Divi's Labs shares.

[ananya5400]

Lycopene Market to Witness Unprecedented Growth in Coming Years

The global lycopene market is projected to reach USD 161 million by 2025, recording a CAGR of 5.0% during the forecast period. The market is primarily driven by the increasing number of benefits offered by lycopene in preventive healthcare and its rising applications in an array of industries, globally.

Download PDF Brohure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104131737

Rising consumption of lycopene in an array of industries due to its functions as a health ingredient and coloring agent

Lycopene is witnessing a rise in consumption in an array of industries including dietary supplements, food, personal care & cosmetics, and pharmaceuticals. It is experiencing this growth due to its properties that mainly includes being a health ingredient, followed by being a coloring agent. The majority of the market share in the global lycopene market was accounted for by the health ingredient property. The coloring agent property has a comparatively smaller share in the global market for lycopene. This is a result of the limited application of lycopene as a coloring agent in the food industry. Also, applications of lycopene as a health ingredient are expanding, which is further expected to boost the growth of lycopene in the global market.

Dietary supplements to record the highest CAGR during the forecast period

The demand for dietary supplements is on the rise in developed and developing countries among the millennial population. Lycopene constitutes to be a key ingredient in the dietary supplements consumed by an individual daily. Also, industry experts foresee the adoption rate for dietary supplements to increase the most in the next five years. Hence, lycopene’s key role in the dietary supplement application because of its distinct health benefits is expected to bolster the growth during the forecast period between 2020 and 2025.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=104131737

The lycopene market in the Asia Pacific region is projected to grow at the highest CAGR from 2019 to 2025

Factors driving the growth of the Asia Pacific market include the presence of the lycopene manufacturing companies in this region. In addition, the production of tomatoes is the highest among all the regions, globally resulting in lower cost for procuring raw material. Hence, the development of technologies and abundant raw material leading the manufacturers to produce and supply lycopene to an array of industries at a competitive price and gaining an advantage over the competitors in the other regions. Furthermore, the rising awareness on benefits of lycopene in food, dietary supplement, and personal care & cosmetic applications is expected to boost the demand for lycopene, also resulting in higher exports from the surplus production of lycopene in this region, which will further boost the market share of this region in the global lycopene market.

Key players operating in this market include Allied Biotech Corporation (China), Lycored (Israel), DSM (Netherlands), Wellgreen Technology Co Ltd (China), Divis Labs (India), San-Ei Gen F.F.I., Inc (Japan), Dangshang Sannuo Limited (China), DDW (US), Dohler (Germany), Farbest Brands (US), Zhejiang NHU CO. Ltd (China), EID Parry (India), Shaanxi Kingsci Biotechnology Co. Ltd (China), Vidya Herbs (India), Xi’an Pincredit Biotech Co Ltd (China), Hunan Sunshine Bio-Tech Co.Ltd (China), Xi’an Natural Field Bio-Technology Co.,Ltd (China), Plantnat (China), SV AgroFoods (India), and Plamed Green Science Group (China).

[newsbunddle]

Divi's Laboratories' Share Jumps 18%, Emerges As Second Most Valuable Pharma Company

Divi’s Laboratories’ Share Jumps 18%, Emerges As Second Most Valuable Pharma Company

[ad_1]

New Delhi: At a time when the markets are extremely volatile, pharma company Divi’s Laboratories Ltd managed to topple drugmakers Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd and Cipla Ltd and emerged as the second most valuable listed pharmaceutical company. Also Read: Saudi Arabia Stops Supply Of Oil To Pakistan; Deal Put Off Due To Deferred Payments

On Monday,…

[goldsilverreports]

API Suppliers In Focus; Divi's Labs, Laurus Labs Advance

API Suppliers In Focus; Divi’s Labs, Laurus Labs Advance

Asian vaccine stocks followed their global peers lower, with Shanghai Fosun dropping by as much as 21% in Hong Kong, after Merck & Co. said its experimental antiviral pill cuts the risk of hospitalization and death from Covid-19 in half. (more…)

[techmaqofficial]

Divi’s Labs Surges 16% To Hit New 52-Week High On Strong Earnings Divi's Labs shares traded 12 per cent higher at Rs 3,122. Divi's Labs surged as much as 16 per cent to hit a fresh 52-week high of Rs 3,228.05 on the BSE after the company on Saturday reported that its annual profit after tax rose 80 per cent in quarter ended June 30 to Rs 492.10 crore.

[newzzhub]

Divi’s Labs Surges 16% To Hit New 52-Week High On Strong Earnings Divi's Labs shares traded 12 per cent higher at Rs 3,122. Divi's Labs surged as much as 16 per cent to hit a fresh 52-week high of Rs 3,228.05 on the BSE after the company on Saturday reported that its annual profit after tax rose 80 per cent in quarter ended June 30 to Rs 492.10 crore.

[ddtvnews]

Divi’s Labs Surges 16% To Hit New 52-Week High On Strong Earnings Divi's Labs shares traded 12 per cent higher at Rs 3,122. Divi's Labs surged as much as 16 per cent to hit a fresh 52-week high of Rs 3,228.05 on the BSE after the company on Saturday reported that its annual profit after tax rose 80 per cent in quarter ended June 30 to Rs 492.10 crore.

[vilaspatelvlogs]

डिवीज लैब के सीएफओ सहित सात लोगों पर इनसाइडर ट्रेडिंग का आरोप, सेबी ने 96 लाख रुपए पेनाल्टी लगाई

डिवीज लैब के सीएफओ सहित सात लोगों पर इनसाइडर ट्रेडिंग का आरोप, सेबी ने 96 लाख रुपए पेनाल्टी लगाई

[ad_1]

सेबी ने जांच के दौरान कंपनी के सीएफओ सहित सात लोगों को आरोपी पाया

डिवीज लैब का शेयर सुबह 5 प्रतिशत गिरावट के साथ कारोबार कर रहा था

दैनिक भास्कर

Jul 02, 2020, 02:11 PM IST

मुंबई. पूंजी बाजार नियामक सेबी ने गुरुवार को डिवीज लैब के मुख्य वित्तीय अधिकारी (सीएफओ) सहित सात लोगों पर 96 लाख रुपए की पेनाल्टी लगाई है। यह पेनाल्टी शेयरों में इनसाइडर ट्रेडिंग के मामले में लगाई गई है। डिवीज लैब का…

[techvercy]

Divi's Labs share price: Can Divi's maintain its premium valuation amid headwinds?

Divi’s Labs share price: Can Divi’s maintain its premium valuation amid headwinds?

Synopsis Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have…

[classyfoxdestiny]

ASK AJIT: Are these stocks good to hold for one year?

ASK AJIT: Are these stocks good to hold for one year?

‘Should I hold , exit or accumulate in 1-3 months short term and 1+ year long term?’

  Ajit Mishra, vice president, Research, Religare Broking, answers your queries:

Chidambarasamy Manickam: Can you let me know if I should hold or exit the below scripts please?

Ajit Mishra:

Company No of shares Price Recommendation HCL Info Systems 1,905 Rs 18.50 Exit Indian Railway Finance Corporation 575 Rs 26 Hold ONGC 85 Rs 145 Hold Sun TV 255 Rs 566 Exit South Indian Bank Limited 3,360 Rs 18.50 Prefer ICICI Bank TV18 Broadcast Limited 1,575 Rs 36 Exit Yes Bank 225 Rs 55 Exit if not under lock-in

  Sriparna Mondal: I have the following stocks for the past 4-5 years. Other than the ETF, almost all are down 50 per cent from the purchase price. Does it make sense to hold the stocks any longer or how should I exit and what stocks I can buy in lieu? Please advise.

Ajit Mishra:

Company No of shares Price Recommendation BSE 90 Rs 1,013 Hold ICICI ETF 1,152 Rs 113 NA (Which ETF?) JK Tyre 250 Rs 173 Hold SML Isuzu 50 Rs 1,006 Prefer Ashok Leyland Tata Motors 100 @442 Prefer Ashok Leyland

    Deepti Ambadipudi: Bought 100 shares of Bambino Agrotech at Rs 211. Should I hold, exit or add? Please guide me. 

Ajit Mishra: Exit

  Srinu Kodi: I have been seeing your opinion on many people’s portfolios and I am thankful for your unbiased review.

Recently, I have purchased these stocks with some conviction, wrt long term like 2-3 years as of now or more. I would like to have your view once if possible.

I am not in panic mode looking at market conditions as of now as I know these are quality stocks I have invested in.

Note: I purchased Gland Pharma for the short term recently as I see some potential till the time Covid is there, as it is doing vaccine manufacturing for Sputnik. I am thinking about profits for Gland Pharma.

Could you please tell me if I can hold this or sell after it reaches Rs 2,800 level? Please tell me if I can hold this for the long term.

Ajit Mishra: Yes, one can hold for long term

  Company No of shares Price Recommendation AUBANK 20 Rs 1,008.40 Hold BAJFINANCE 3 Rs 4,411.30 Hold DFM 56 Rs 333.86 Prefer Britannia DIXON 14 Rs 3,643.18 Hold DMART 9 Rs 2,854.99 Hold GLAND 39 Rs 2,542.81 Hold HDFCBANK 15 Rs 1,399.54 Hold ICICIGI 29 Rs 1,354.63 Hold INDIAMART 5 Rs 7,873.97 Hold JUBLFOOD 7 Rs 2,757.75 Hold MCDOWELL-N 51 Rs 513.71 Hold MUTHOOTFIN EVENT 17 Rs 1,129.30 Hold NAUKRI 10 Rs 4,622.06 Hold RELIANCE 12 Rs 1,911.23 Hold SYNGENE 70 Rs 602.38 Hold

  Sukanta Mandal: Need your suggestion on these — whether to hold, exit or accumulate — in 1-3 months short term and 1+ year long term. Awaiting your thoughts and views.

Ajit Mishra:

Company Recommendation Ashok Leyland Hold JK Tyre Hold Bank of Baroda Prefer SBI HDFC bank Hold Shree Digvijay Cement Prefer Ultratech/Ambuja Coal India Exit Gujarat Mineral Development Co Hold Indian Railway Catering and Tourism Corporation Hold Jaiprakash Power Exit NTPC Hold NHPC Hold HFCL Ltd Hold United Spirits Hold EIH Exit JSW Energy Ltd Hold

  Rohith Adiga: I am a starter in the stock market and trading from the last six months. Below is the list of stocks I have purchased. Advise me about buying additional stock, or holding or selling.

I am also looking for a short term plan of 6-10 months starting from June. Please suggest from my existing stock list or a new stock for short term gain. Also would like to know when to purchase the additional stock, when it’s growing or when it dips.

For example, I purchased 50 shares of Tata Motors @ Rs 124, then added another 25 when it went to @ Rs 185 and again purchased 10 @ Rs 290. Now my average pricing is @ Rs 244.

Ajit Mishra:

Company No of shares Price Recommendation HAL 5 Rs 1,100.96 Hold BIOCON 1 Rs 459 Hold ZEEL 5 Rs 224.4 Exit ITC 5 Rs 210.45 Hold HDFCBANK 1 Rs 1,377.60 Hold and buy on dips L&TFH 15 Rs 84.62 Hold ASIANPAINT 3 Rs 2,039.53 Hold HCLTECH 6 Rs 758.96 Hold AXISBANK 6 Rs 547.89 Hold RELIANCE 5 Rs 1,720.75 Hold TATAMOTORS 25 Rs 244.71 Hold for 2-3 years at least KOTAKBANK 5 Rs 1,369.65 Hold INFY 10 Rs 972.27 Hold TCS 5 Rs 2,318.60 Hold BAJFINANCE 2 Rs 3,636.00 Hold

  Jasminkumar Maheshbhai Gajjar: I have been following your posts on a regular basis. I have invested for long/mid-term. Request you to advise for the below stocks held by me.

Ajit Mishra:

Company No of shares Price View Recommendation Alok Industries 350 Rs 22.78 Mid-term Exit Bandhan Bank 50 Rs 348.43 Long-term Hold Bharat Elec Ltd 75 Rs 134.71 Mid-term Hold Biocon 30 Rs 410.81 Mid-term Hold Burger King 50 Rs 132.38 Long-term Hold Cyient 15 Rs 690.22 Mid-term Hold Firstsource Sol 80 Rs 116.64 Mid-term Hold India Cements 60 Rs 168.43 Mid-term Hold Inox Leisure 30 Rs 332.34 Mid-term Hold J K Tyre 50 Rs 118.32 Long-term Hold Laurus Labs 20 Rs 468.02 Mid-term Hold Manappuram 50 Rs 159.96 Mid-term Hold Motherson sumi 40 Rs 236.75 Mid-term Hold NMDC 50 Rs 157.46 Long-term Hold Spicejet 130 Rs 86.35 Long-term Hold Sun Pharma Adv 50 Rs 183.02 Mid-term Hold Sundaram Fin ltd 6 Rs 2,528.45 Long-term Hold Tata Chemicals 15 Rs 690.82 Long-term Hold Tata Power 75 Rs 92.85 Long-term Hold Tata Steel BSL 100 Rs 96.18 Long-term Hold Time Technopl 75 Rs 84.34 Mid-term Exit Zen Tech 100 Rs 86.60 Long-term Exit

  Rajkumar Dhyani: Namaskar. I’m a small investor who looks for mid and small-cap scrips to invest in. I can invest Rs 5-10K monthly in stocks. I’m looking for a long-term vision, probably 1-2 years vision. Can you please suggest few important scrips which match my requirement?

Ajit Mishra: One can invest in Finolex Industries, Ashok Leyland, INOX Leisure, Exide Industries, Kansai Nerolac.

  Marshall: Please review my portfolio, if I can hold, accumulate or exit from these stocks. I’m not sure of the period if I have to hold these stocks. Please advise.

Ajit Mishra:

Company No of shares Price Recommendation Balaji Amines 20 10 @ Rs 824 and 10 @ Rs 2,500 Hold Laurus Labs 100 50 @ Rs 400 and 50 @ Rs 490 Hold Sun Pharma 10 Rs 60 Hold Wock Pharma 10 Rs 590 Hold Eicher Motors 10 Rs 2,520 Hold Titan 10 5 @ Rs 1,126 and 5 @ Rs 1450 Hold Tech Mahindra 10 Rs 1,000 Hold TataSTLBSL 50 Rs 100 Hold Poly Cab 10 Rs 1,480 Hold SUN TV 10 Rs 520 Exit Adani Power 100 Rs 100 Exit Larsen and Turbo 10 Rs 1,450 Hold

  Rane Tushar: I hold following stocks. Which should I hold and which should I exit?

Ajit Mishra:

Company No of shares Recommendation IOB 60 Exit URJA 5,000 Exit TTML 700 Hold for 2-3 years DHFL 203 Exit GMBREW 85 Hold GRAPHITE 96 Hold NOCIL 942 Hold PRAKASH 965 Exit

  Sunil: I want to invest Rs 2 lakhs rupees for long term. Please suggest and guide me about some good equity shares.

Ajit Mishra: Bharti Airtel, ICICI Bank, Nippon AMC, Britannia Industries, Maruti Suzuki

  GOPAL CHAKRABORTY: I am holding the following mentioned stocks for the long term. Kindly advise.

Ajit Mishra:

Company No of shares Price Recommendation Tata Steel 220 Rs 470 Hold Suzlon Energy 2,300 Rs 5.70 Exit Tilaknagar Industries 600 Rs 72 Exit Clariant Chemicals 59 Rs 598 Hold NCC Ltd 213 Rs 67 Exit Suven Lifescience 175 Rs 62 Hold HCC Ltd. 180 Rs 57 Exit Andhra cements 1,200 Rs 23 Prefer Ultratech Educomp 2,200 Rs 190 Exit Yes Bank 2,500 Rs 17.50 Exit Gufic Bioscience 135 Rs 167 Hold

  Shyam Kannacham Veettil: I would like to have hold/exit strategy for following stocks. I can hold long term

Ajit Mishra:

Stock Unit holding Average price Recommendation Bandhan Bank 30 Rs 303 Hold Federal Bank 500 Rs 57 Hold HDFC AMC 60 Rs 1,733 Hold HDFC Standard Life 260 Rs 300 Hold SBI Card 30 Rs 770 Hold Yes bank 1,000 Rs 116 Exit if not under lock-in. Dixon Tchnology 100 Rs 917 Hold Havells 600 Rs 302 Hold V guard 550 Rs 185 Hold L&T 105 Rs 1,117 Hold Tata consumer products 160 Rs 367 Hold Varun Beverages 380 Rs 435 Hold Jubilant food 25 Rs 1,846 Hold First source solutions 1,000 Rs 55 Hold Tata elxi 30 Rs 851 Hold IRCTC 20 Rs 1,309 Hold Berger Paints 90 Rs 560 Hold Petronet LNG 925 Rs 115 Hold Adani Port 100 Rs 230 Hold

  Rajesh Nair: I have 50 shares of Dixon Technologies at an average price of Rs 3,742. If I am looking at holding these for a horizon of three years, should I hold/accumulate or exit these ?

Ajit Mishra: Hold the stock. Accumulate on dips only.

  Nitesh Shah: I have these shares. Can you advise if I can hold, sell or buy more?

Ajit Mishra:

Stock Average of investment price Recommendation Aarvee Denim Rs 19.4 Exit AB Capital Rs 59.9 Exit Aditya Birla F Rs 136 Prefer Titan AFL Rs 13.7 Exit Aishwarya Tech Rs 34.3 Exit Albert David Rs 464 Exit Alok Industries Rs 60.9 Exit Amara Raja Batteries Rs 873 Hold Arvind Rs 55.8 Exit Arvind Smart Rs 91 Exit Ashtavinayak Rs 6 Exit Aster DM Health Rs 174 Hold Avenue Supermarts Rs 299 Hold Bajaj Consumer Rs 316 Hold Bandhan Bank Rs 340 Hold Bank of Baroda Rs 46.5 Exit BEML Rs 762 Exit Berger Paints Rs 160 Hold Bharti Airtel Rs 537 Hold BHEL Rs 37.5 Exit Binani Cement Rs 85 Exit Canara Bank Rs 168 Exit Cigniti Tech Rs 430 Exit Cipla Rs 474 Hold Coal India Rs 143 Exit Cosmo Films Rs 633 Exit CreditAccess Grameen Rs 702 Hold Cummins Rs 732 Hold Dalmia Bharat Rs 789 Hold Deepak Nitrite Rs 668 Hold Digjam — BSE Rs 26.4 Exit Diligent Media Re 1 Exit Dishman Carbogen Rs 161 Hold Divis Labs Rs 2,484 Hold D-Link India Rs 113 Exit Dollar Industries Rs 450 Hold Endurance Technologies Rs 1,444 Hold Eveready Industries Rs 374 Hold Fortis Health Rs 108 Hold Ganesha Ecosphere Rs 18.7 Exit General Insurance Rs 456 Prefer ICICI Lombard Glenmark Rs 515 Hold Godawari Power Rs 201 Exit Granules India Rs 343 Hold Grasim Rs 667 Hold GTL Infra

Rs 80.5

Exit GV Films Rs 7.75 Exit GVK Power Rs 35.1 Exit HBL Power Rs 57.7 Exit HCL Tech Rs 348 Hold HDFC Rs 1,217 Hold HDFC Life Rs 688 Hold HFCL Rs 27.9 Hold Hindustan Construction Rs 43 Exit Hindustan Zinc Rs 218 Hold HUDCO Rs 82.9 Hold ICICI Lombard Rs 661 Hold ICICI Prudential Rs 402 Hold IDFC First Bank Rs 57.8 Exit IFCI Rs 18 Exit IKF Tech – BSE Rs 6.93 Exit Indian Acrylics Rs 10 Exit Indo Count Rs 85.5 Exit Indostar Capita Rs 572 Hold Infomedia Press Rs 24.4 Exit Infosys Rs 555 Hold Interworld Rs 3.89 Exit IOB Rs 42.4 Exit IOC Rs 125 Hold Ion Exchange Rs 677 Hold IRFC Rs 26 Hold ITC Rs 216 Hold Jenson Nicholson Rs 16.2 Exit Jindal SAW Rs 80.8 Hold JSW Steel Rs 228 Hold Kajaria Ceramics Rs 422 Hold L&T Finance Rs 82.8 Hold Larsen Rs 837 Hold LIC Housing Finance Rs 353 Hold M&M Financial Rs 165 Hold Maharashtra Seamless Rs 500 Exit Marathon Realty Rs 67.6 Exit Maruti Suzuki Rs 6,632 Hold Max Healthcare Rs 78.9 Hold Max India Rs 391 Hold Mirc Electronic Rs 51.1 Exit MOIL Rs 156 Hold Munjal Showa Rs 61.4 Exit Nahar Poly Film Rs 48.1 Exit National Steel Rs 27 Exit Network 18 Rs 33 Exit New India Assurance Rs 400 Prefer HDFC Life Newgen Software Rs 245 Hold NHPC Rs 31.5 Hold Nippon ETF Gold Rs 35.5 Hold NOCIL Rs 157 Hold NTPC Rs 146 Hold ONGC Rs 139 Hold Paramount Communications Rs 28 Exit Pennar Industries Rs 23.3 Exit Pidilite Industries Rs 1,773 Hold Power Grid Corporation Rs 145 Hold Precision Electricals Rs 14.7 Exit Precision Wires Rs 80 Exit Raj Oil Mills Rs 10 Exit Rajapalayam Rs 348 Hold RBL Bank Rs 526 Hold Reliance Rs 1,482 Hold Reliance Communications Rs 2.55 Exit Reliance Power Rs 232 Exit Rico Auto Rs 38 Exit Saregama India Rs 767 Exit SBI Rs 270 Hold SBI Life Insurance Rs 700 Hold SGN Cable Rs 0.42 Exit Siti Networks Rs 32.5 Exit South Indian Bank Rs 25.8 Exit Sumeet Industries Rs 14.2 Exit Sun Pharma Rs 893 Hold TAEL Rs 0.24 Exit Talbros Auto Rs 307 Exit TCS Rs 198 Hold Tech Mahindra Rs 574 Hold Terruzzi Fercalx Rs 50.7 Exit Tirupati Foam Rs 10 Exit TV18 Broadcast Rs 48.1 Hold Unitech Rs 1.95 Exit Usha Martin Rs 1.25 Exit Usha Martin Edu Rs 1.25 Exit UTI AMC Rs 554 Prefer HDFC AMC or Nippon AMC Varroc Engineer Rs 421 Hold Vascon Engineer Rs 46.7 Exit Visa Steel Rs 53.5 Exit VRL Logistics Rs 432 Hold Wipro Rs 254 Hold Zee Media Rs 41.1 Exit

  Please mail your questions to getahead@rediff.co.in with the subject line ‘Ask Ajit’, along with your name, and Mr Ajit Mishra will offer his unbiased views.

Disclaimer: This article is meant for information purposes only. This article and information do not constitute a distribution, an endorsement, an investment advice, an offer to buy or sell or the solicitation of an offer to buy or sell any securities/schemes or any other financial products/investment products mentioned in this QnA or an attempt to influence the opinion or behaviour of the investors/recipients.

Any use of the information/any investment and investment related decisions of the investors/recipients are at their sole discretion and risk. Any advice herein is made on a general basis and does not take into account the specific investment objectives of the specific person or group of persons. Opinions expressed herein are subject to change without notice.

Feature Presentation: Ashish Narsale/ Rediff.com

. Source link

[techsciresearch]

India Active Pharmaceutical Ingredients Market to Grow at a CAGR of 12.24% During the Forecast Period

Increasing incidence of chronic diseases is expected to drive the growth of India Active Pharmaceutical Ingredients market during the forecast period.

According to TechSci Research report, “India Active Pharmaceutical Ingredients Market By Method of Synthesis (Synthetic v/s Biological), By Source (Contact Manufacturing Organizations v/s In-house Manufacturing), By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type (Generics v/s Innovator), By Region, Competition Forecast & Opportunities, FY2027F”, India active pharmaceutical Ingredients market stood at USD11806.93 million in FY2021 and is expected to grow at a formidable rate of 12.24% during the forecast period owing to improvement in healthcare infrastructure coupled with continuous advancements in active pharmaceutical ingredients (API) manufacturing. However, there are some challenges that hinder the growth of active pharmaceutical market such as unfavorable drug price control policies across various nations and high manufacturing costs and regulatory stringencies.

Browse 21 Figures spread through 70 Pages and an in-depth TOC on " India Active Pharmaceutical Ingredients Market"

https://www.techsciresearch.com/report/india-active-pharmaceutical-ingredients-market/7277.html

The India active pharmaceutical ingredients market is segmented based on method of synthesis, source, therapeutic application, drug type, company, and region. Based on source, the market can be further categorized into in-house v/s contract manufacturing organizations. The contract manufacturing segment dominated the market with 70.20% share in FY2021 as most of the leading companies give license to smaller companies for manufacturing the drugs which allows them to meet the demands of the market. Furthermore, it allows them to focus more on research and development of new drugs. Contract manufacturing organizations also save cost and maximizes profit. Rising number of contract manufacturers will contribute to the growth of contract manufacturing organizations segment during the forecast period at a CAGR of 12.77%.

Teva API India Limited, Pfizer Ltd., Ipca Laboratories Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Aurobindo Pharma Limited, Aarti Drugs Ltd., IOL Chemicals and Pharmaceuticals Limited, Divis Laboratories Ltd., Granules India Limited, Laurus Labs Ltd., Solara Active Pharma Sciences, GlaxoSmithKline Pharmaceuticals Ltd, and others are some of the major players operating in the India active pharmaceutical ingredients market. Major companies are developing advanced technologies, receiving approvals from regulatory bodies, and launching new products to stay competitive in the market. Other inorganic growth strategies include mergers & acquisitions, research collaborations, joint ventures, and new product developments to sustain themselves amidst fierce competition. Many companies have applied for Production Linked Incentive Scheme for manufacturing active pharmaceutical ingredients. Which will provide incentives and profits to the companies. RMC Performance Chemicals Private Limited has got approval for production of active pharmaceutical ingredient via Production Linked Incentive Scheme with a capacity of 15000MT of Aspirin.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7277

Customers can also request for 10% free customization on this report.

“India Active Pharmaceutical Ingredients market is expected to grow at robust rate during the forecast period which is attributable to increasing uptake of biopharmaceuticals. Additionally, major market players are focusing on strategic collaborations to commercialize their newly developed drugs. This is further expected to create lucrative opportunities for the market growth of India Active Pharmaceutical Ingredients market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“India Active Pharmaceutical Ingredients Market By Method of Synthesis (Synthetic v/s Biological), By Source (Contact Manufacturing Organizations v/s In-house Manufacturing), By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type (Generics v/s Innovator), By Region, Competition Forecast & Opportunities, FY2027F”, has evaluated the future growth potential of India active pharmaceutical ingredients market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India active pharmaceutical ingredients market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Web:   https://www.techsciresearch.com/

[brainmassfinance]

Divi's Labs m-cap crosses Rs 1 trillion; stock zooms 109% in CY 2020 so far

Currently, Divis Labs stands at the 30th position among companies having market-cap of over Rs 1 trillion.

Divi’s Laboratories entered the elite club of companies with a market capitalisation (market-cap) of Rs 1 trillion after the firm's stock price hit a new high of Rs 3,832, up 3 per cent, on Thursday.

The stock of the pharmaceutical company surpassed its previous high of Rs 3,763.40, touched on December 10, 2020.

At 10:05 am, Divi’s Labs' market-capitalisation stood at Rs 1.01 trillion, exchange data show.

Currently, Divis Labs stands at the 30th position among companies having market-cap of over Rs 1 trillion. It is the second most valued pharma company after Sun Pharmaceutical Industries, which has market-cap of Rs 1.40 trillion, data show.

So far in the calendar year 2020, the share price of Divi’s Labs has zoomed 109 per cent, as compared to a 13 per cent rise in the S&P BSE Sensex and a 60 per cent jump in the S&P BSE Healthcare index.

The company, on December 1, had announced the commencement of construction of Divi's Laboratories Unit-III facility (the project) at Kona Forest, Ontimamidi village, Andhra Pradesh from December 7, 2020.

The company said it will be investing about Rs 1,500 crore out of its internal accruals in a phased manner for the implementation of its Unit-III facility. The operations are likely to commence within 12 to 18 months for the first phase of the Project.

“Divi’s Labs is one of the largest generic API (active pharmaceutical ingredient) manufacturers globally and has a successful track record of executing custom synthesis business for innovator customers. Strong positioning of Divi's will help the company in monetising the growth opportunity in API and CRAMS (contract research and manufacturing services) space given its stellar execution track record and it being one of the preferred suppliers,” analysts at ICICI Securities said in a report.

Recent and planned capex of Rs 2,200 crore reinforces our view as Divis is known for expanding capacities with very high business visibility, the report added.

Key moats of the company have been continuous process innovation, low-cost production, talent retention and longstanding relationships with customers, the brokerage firm said as it initiated coverage on the stock with 'ADD' rating and a target price of Rs 3,960 per share.

[superpruchika99world]

Flipkart's Bansals no more billionaires, Patanjali's Bala now worth $3.6 bn

Economy & Policy Flipkart founders Sachin and Binny Bansal, who earned dollar billionaire status last year and whose wealth has fallen with successive markdowns of their firm’s valuation, are among the 31 Indian billionaires who are out of the Hurun Global Rich — Indian billionaires report.

Eleven of the 31 have lost their billionaire status since demonetisation. Prominent among them are Gautam Thapar of Crompton Greaves, Nilima Motaparti of Divi’s Labs, Prathap C Reddy & family of Apollo Hospitals, and Nandan Nilekani, an Infosys shareholder.

ALSO READ: Canada to review $6.8 mn worth security equipment purchased from China

This list is exclusively based on the share price performance of companies after demonstration. However, many billionaires have seen their wealth soaring.

The cumulative wealth of 132 Indian or Indian-origin billionaires is estimated to have increased to $392 billion, up 16 per cent from last year, says the report...Read more.

[tradeniveshinvestmentadvisor]

Continuation of fast may continue in the market | Trade Nivesh

Trade Nivesh | The stock market continues to boom. Major indices are at peak levels. On the basis of technical signals, the market will continue to boom. Based on the daily charts of 30 October, the Sensex had formed a 'Golden Cross' shape, which is pointing to the continuation of the boom. The Sensex reached the top level on this day.

The Golden Cross is a strong technical signal, indicating that bulls are dominating the market. Under this, the normal trading average of short duration (50 sessions) goes above the normal trading average of long term (200 sessions).

The 30-share Sensex has an average of 50 trading sessions at 39,878. While the average of 200 trading sessions is close to 38,859. The Sensex closed on a new peak on Monday. Analysts believe that the index could grow by 5–16 per cent in the next 6 to 12 months.

According to Sahil Kapoor, chief market strategist and assistant director of Edelweiss, the Sensex could reach between 46,000 and 47,000 by June 2020. According to G Chokkalingam of Equinomics Research and Advisory, by March 2020, the Sensex may register a 5 to 8 per cent rise.

The NSE Nifty 50 index is also seen making 'Golden Cross'. According to Nirav Chheda, Senior Technical Analyst, Nirmal Bang, "The upper and lower levels are steadily rising. The average of 50 sessions stands on the verge of rising above the average of 200 sessions."

Naveen Kulkarni, head of research, Reliance Securities, said that the index will only grow from here and may reach 12,800 by April 2020. Golden cross is seen in many stocks on the index. These stocks are also showing signs of rising.

These include Larsen & Toubro, Ajanta Pharma, Dr. Reddy's Labs, Ramco Cements, Divis Labs, Reliance Industries, Avanti Feeds, Tata Consultancy Services, Hero MotoCorp, HDFC, SJVN, Gulf Oil and Adani Ports. Golden Cross is seen forming in more than 100 stocks on the BSE 500 index.

Among the Sensex stocks, analysts are positive on Larsen & Toubro, which represents the Golden Cross. The company earned a net profit of Rs 2,770.43 crore in the September quarter, up 6.83 percent from a year earlier.

Morgan Stanley has given a target price of Rs 1,753 crore to the stock. Whereas CLSA believes that this stock can reach Rs 1,730. According to brokerage firm Macquarie, investing in this stock in a volatile market can benefit. But this year the stock has gained only 0.73 per cent.

Global brokerage firms do not see much confidence in Hero MotoCorp. CLSA has advised to sell this stock. While Macquarie has taken a 'neutral' stance towards this stock. According to the brokerage, the change in BS-VI can be challenging for the company.

Dr. Reddy's Labs has jumped 17 percent in the last one year. The company earned a net profit of Rs 1,093 crore in the September quarter, compared to Rs 504 crore a year earlier. Credit Suisse has given a target price of Rs 3,055, which is about 9 per cent above the current prices.

[pruchika99-blog]

Flipkart's Bansals no more billionaires, Patanjali's Bala now worth $3.6 bn

Companies news Flipkart founders Sachin and Binny Bansal, who earned dollar billionaire status last year and whose wealth has fallen with successive markdowns of their firm’s valuation, are among the 31 Indian billionaires who are out of the Hurun Global Rich Indian billionaires report.

Eleven of the 31 have lost their billionaire status since demonetisation. Prominent among them are Gautam Thapar of Crompton Greaves, Nilima Motaparti of Divi’s Labs, Prathap C Reddy & family of Apollo Hospitals, and Nandan Nilekani, an Infosys shareholder.

ALSO READ : HCL Tech overtakes Wipro to become third-largest IT services firm in India

This list is exclusively based on the share price performance of companies after demonetisation. However, many billionaires have seen their wealth soaring. The cumulative wealth of 132 Indian or Indian-origin billionaires is estimated to have increased to $392 billion, up 16 per cent from last year, says the report.

Twenty-seven billionaires have been added to the list this year. Of the 27 entrants, Acharya Balakrishna of Patanjali Ayurved leads the pack with wealth of $3.6 billion, followed by Nadir B Godrej and Smitha V Crishna...Read more.